Partnership
We take a long-term, collaborative approach with our partners to empower their genetic medicines
We deliver
Whatever your delivery challenge, we can overcome it… together
With an expansive library of novel lipids and formulations at our disposal, we can tailor an LNP system to meet your delivery needs, whatever the payload or application.
The need for mutation-proof vaccines was highlighted more than ever by the COVID pandemic. We at Baseimmune are tackling this problem by using AI to design next-generation antigens. We partnered with NanoVationtx™ to deliver these antigens using next-generation lipid nanoparticles, creating mRNA vaccines of the future.
Our company has high standards for the products and people we work with. Not only does NanoVationtx™ develop and deliver best-in-class technology, they share our vision to carry out the best science for the benefit of humankind.
Synthetic chemistry & RNA synthesis
Formulation
Preclinical studies
All the way
We’re in it with you, from start to finish
NanoVation Therapeutics™ can collaborate with you from end-to-end in the drug development process.
Our expertise covers mRNA synthesis and LNP formulation, through to preclinical trials and delivery optimization.
Once we’ve overcome your delivery challenge, we also offer you the option to license our toolbox.
Our pipeline
Filter by tissue
Filter by therapeutic area
Durable gene expression for treating genetic diseases
Adminstration route: i.v.
Platform technology: HepLNP
Modality: DNA
Indication: not disclosed
Strategy: partnership
Gene editing in extrahepatic tissues for treating genetic diseases
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: mRNA/gRNA
Indication: not disclosed
Strategy: partnership
Gene editing in hepatocytes for genetic disease
Adminstration route: i.v.
Platform technology: HepLNP
Modality: mRNA/gRNA
Indication: not disclosed
Strategy: Partnered
Gene expression for cancer immunotherapy
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: mRNA
Indication: not disclosed
Strategy: internal
Gene expression for healthy aging
Adminstration route: i.v.
Platform technology: combined
Modality: mRNA
Indication: not disclosed
Strategy: internal
Gene expression in tumors
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: DNA
Indication: not disclosed
Strategy: partnership
Gene silencing in hepatocytes for genetic disease
Adminstration route: i.v.
Platform technology: HepLNP
Modality: siRNA
Indication: not disclosed
Strategy: partnership
Gene silencing in skin and adipose tissues for genetic disease
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: siRNA
Indication: not disclosed
Strategy: partnership
mRNA vaccine for viral diseases
Adminstration route: i.m.
Platform technology: combined
Modality: mRNA
Indication: SARS & ASF
Strategy: partnership
Finding solutions together
Let’s discuss how our proprietary platform technologies can help rapidly translate your nucleic acid therapeutic or vaccine into the clinic.